Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
About this study
The purpose of this study is to determine whether giving extra arginine to patients with sickle cell disease seeking treatment for vaso-occlusive painful events (VOE) will decrease pain scores, decrease need for pain medications or decrease length of hospital stay or emergency department visit.
- Condition
- Sickle Cell Disease
- Tested
- Arginine, Arginine (Loading), Arginine (Continuous)
- Sponsor
- Emory University
Who can join
- Age
- 7 to 21 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 7 years
- Maximum age: 21 years
- Study condition: Sickle Cell Disease
- Established diagnosis of sickle cell disease--Hemoglobin SS (Hb-SS) or Sβᴼ-thalassemia
- 7-21 years of age
- Weight \>= 25kg (55lbs)
- Pain requiring medical care in an acute care setting (emergency department (ED), hospital ward, day hospital, clinic) requiring parenteral opioids, not attributable to non-sickle cell causes.
Exclusion 12
- Decision to discharge home from acute care setting.
- Diagnosis of sickle cell disease with any of the following types: hemoglobin SC disease (HbSC), hemoglobin beta thalassemia (Hb-Beta Thal), hemoglobin SD disease (HbSD), hemoglobin SE disease (HbSE), hemoglobin SO disease (HbSO), hemoglobin AS carrier (Hb AS)
- Hemoglobin less than 5 gm/dL
- Immediate Red cell transfusion anticipated
- Renal dysfunction: Creatinine \>1.0 or 2 x baseline
- Mental status or neurological changes
- Acute stroke or clinical concern for stroke
- Pregnancy
- Allergy to arginine
- Previous hospitalization \< 7 days
- Use of inhaled nitric oxide, sildenafil or arginine within the last 14 days
- Not an appropriate candidate in the investigator's judgement
Where
2 sites, 2 recruiting
Children's Healthcare fo Atlanta at Hughes Spalding
Atlanta, Georgia, United States
Children's Healthcare of Atlanta at Arthur M. Blank Hospital
Atlanta, Georgia, United States
Contact
-
Reshika Mendis, MBBS
404-785-4525 Reshika.mendis@choa.org
-
Claudia Morris, MD
404 727-5500 claudia.r.morris@emory.edu
Potential match only. Final eligibility is determined by the study team.